Therapy with lipid-altering agents should be only one component of multiple risk factor intervention in individuals at significantly increased risk for atherosclerotic vascular disease due to hyperlipidemia. Niacin therapy is indicated as an adjunct to diet when the response to a diet restricted in saturated fat and cholesterol and other nonpharmacologic measures alone have been inadequate. 1.NIASPAN is indicated to reduce elevated TC, LDL-C, Apo B, and TG levels, and to increase HDL-C in patients with primary hyperlipidemia and mixed dyslipidemia. 2.NIASPAN in combination with simvastatin or lovastatin is indicated for the treatment of primary hyperlipidemia and mixed dyslipidemia when treatment with NIASPAN, simvastatin, or lovastatin monotherapy is considered inadequate. 3.In patients with a history of myocardial infarction and hyperlipidemia, niacin is indicated to reduce the risk of recurrent nonfatal myocardial infarction. 4.In patients with a history of coronary artery disease (CAD) and hyperlipidemia, niacin, in combination with a bile acid-binding resin, is indicated to slow the progression or promote regression of atherosclerotic disease. 5.NIASPAN in combination with a bile acid-binding resin is indicated to reduce elevated TC and LDL-C levels in adult patients with primary hyperlipidemia.